GlassScriptPhysician profile
Byron Carrasco
NPI 1356641476
$3,325.39
in general payments reported to CMS, 2019-2025
20 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $98.05 · 2021: $50.39 · 2022: $348 · 2023: $301 · 2024: $704 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Long Term Medical Supply Or Device Loan: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.81 |
| Long Term Medical Supply Or Device Loan | $362.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $632.05 | 2019-2025 | Apligraf, Puraply, Puraply Wound Matrix |
| Abbvie INC. | $621.77 | 2021-2025 | Dalvance, Teflaro |
| Orthofix Medical, INC. | $397.55 | 2023-2025 | Physio-Stim, Accelstim, Cervical-Stim |
| Integra Lifesciences Corporation | $362.32 | 2025 | Integra |
| Allergan, INC. | $280.68 | 2019 | |
| Smith+Nephew, INC. | $162.62 | 2022-2024 | Oasis, Grafix Pl |
| Travere Therapeutics, INC. | $142.22 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $127.25 | 2022 | |
| Osiris Therapeutics INC. | $120.40 | 2019 | |
| Stability Biologics, LLC | $95.57 | 2024 | |
| Horizon Therapeutics Plc | $78.66 | 2021-2023 | Krystexxa |
| Trimed, INC. | $72.37 | 2025 | |
| Bone Support INC. | $62.25 | 2024 | Cerament G, Ceramentbone Void Filler |
| Kowa Pharmaceuticals America, INC. | $57.67 | 2023 | Seglentis |
| Mimedx Group, INC. | $32.04 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.25 | 2025 | Krystexxa |
| Solventum Corporation | $16.86 | 2024 | Prevena, V.A.C. Dermatac, Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $16.69 | 2023 | Nuzyra |
| Ibsa Pharma INC. | $13.12 | 2023 | Tirosint, Licart |
| Baudax Bio INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Carrasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.